Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 11/20 | 0.44 |
| ▸ | CYP26A1 | O43174 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | CYP27A1 | Q02318 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL552196 | 1.00 | MIF (0.44) | MIFCYP26A1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL8210140 | 1.00 | MIF (0.44) | MIFCYP26A1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL551277 | 0.81 | MAOB (0.44) | MIFALDH1A1MAPTSMN1; SMN2LMNA | |
| SCHEMBL551276 | 0.81 | MAOB (0.44) | MIFALDH1A1MAPTSMN1; SMN2LMNA | |
| SCHEMBL13548832 | 0.78 | MAPK14 (0.56) | ALDH1A1MAPTSMN1; SMN2MAPK14KDM4E | |
| SCHEMBL552388 | 0.77 | ALDH1A1 (0.44) | MIFCYP26A1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL8212709 | 0.77 | SMN1; SMN2 (0.46) | MIFCYP26A1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL8211175 | 0.77 | ALDH1A1 (0.44) | MIFCYP26A1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL550954 | 0.77 | SMN1; SMN2 (0.46) | MIFCYP26A1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL552389 | 0.77 | ALDH1A1 (0.44) | MIFCYP26A1ALDH1A1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035131-A1 | PYRAZOLINE COMPOUNDS | PFIZER INC | 2012-02-09 | — | — | US | disclosed |
| EP-2089367-B1 | PYRAZOLINE COMPOUNDS AS MINERALOCORTICOID RECEPTOR ANTAGONISTS | PFIZER PROD INC (US) | 2011-12-14 | — | — | EP | disclosed |
| US-20100280016-A1 | PYRAZOLINE COMPOUNDS | PFIZER INC | 2010-11-04 | — | — | US | disclosed |
| US-7781428-B2 | Cardiovascular disorders; liver disorders ; vascular system disorders; antiinflammatory agents; analgesics ; edema; hypotensive agents | PFIZER INC. (US) | 2010-08-24 | — | — | US | disclosed |
| EP-2089367-A1 | PYRAZOLINE COMPOUNDS AS MINERALOCORTICOID RECEPTOR ANTAGONISTS | Pfizer Products Incorporated (US) | 2009-08-19 | — | — | EP | disclosed |
| US-20080167294-A1 | Cardiovascular disorders; liver disorders ; vascular system disorders; antiinflammatory agents; analgesics ; edema; hypotensive agents | PFIZER, INC (US) | 2008-07-10 | — | — | US | disclosed |
| WO-2008053300-A1 | PYRAZOLINE COMPOUNDS AS MINERALOCORTICOID RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035131-A1 | PYRAZOLINE COMPOUNDS | F12, CYP3A7, ABCG2 | MIF 4600/4885CYP26A1 1405/4885ALDH1A1 1197/4885 |
| US-20100280016-A1 | PYRAZOLINE COMPOUNDS | F12, CYP3A7, ABCG2 | MIF 4600/4885CYP26A1 1405/4885ALDH1A1 1197/4885 |
| US-20080167294-A1 | Cardiovascular disorders; liver disorders ; vascular system disorders; antiinflammatory agents; analgesics ; edema; hypotensive agents | REN, F3, EDNRB | MIF 3183/4885CYP26A1 149/4885ALDH1A1 279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.